What Is Cagrilintide?
Cagrilintide is a synthetic long-acting amylin analogue — a peptide designed to mimic and extend the biological activity of amylin (also known as islet amyloid polypeptide, IAPP), a 37-amino acid pancreatic hormone co-secreted with insulin from pancreatic beta cells. With a molecular weight of approximately 3,985 Da, cagrilintide incorporates fatty acid acylation to enable albumin binding and extend its plasma half-life to approximately 7 days — supporting a once-weekly dosing profile in research applications.
Cagrilintide has emerged as one of the most scientifically significant metabolic research compounds of the current era, primarily through its complementary mechanism to GLP-1 receptor agonists like Semaglutide and dual agonists like Tirzepatide. While GLP-1 receptor agonism has become the dominant approach in metabolic research, amylin receptor agonism offers a distinct and complementary pathway that has generated substantial research interest for combination protocols.
Amylin Biology: The Context for Cagrilintide Research
Understanding cagrilintide requires understanding amylin’s role in metabolic physiology. Amylin is co-secreted with insulin from pancreatic beta cells in response to meals, functioning as a complementary satiety signal that operates through distinct receptors and mechanisms from insulin and GLP-1.
Amylin’s primary physiological roles include:
- Slowing gastric emptying to reduce the rate of nutrient absorption and postprandial glucose excursions
- Suppressing glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output
- Acting on area postrema and nucleus accumbens in the brainstem to reduce food intake and promote satiety
- Modulating meal size and eating rate through direct CNS effects
In individuals with type 2 diabetes and obesity, amylin secretion is frequently impaired — contributing to the loss of normal postprandial glucose regulation and satiety signaling. This deficit has made amylin receptor agonism a target of significant research interest as a complement to insulin and GLP-1 pathway modulation.
Cagrilintide’s Design Advantages Over Native Amylin
Native amylin has significant limitations as a research tool — it has a very short plasma half-life (minutes), a strong tendency to form amyloid fibrils at physiological concentrations (a property responsible for islet amyloid deposits in type 2 diabetes), and limited solubility. These properties made native amylin impractical for research applications requiring sustained amylin receptor engagement.
Cagrilintide was engineered to address these limitations. Key modifications include amino acid substitutions that dramatically reduce amyloid fibril formation while preserving amylin receptor binding affinity, and a fatty acid acylation that enables albumin binding for extended half-life. The result is a stable, soluble, long-acting amylin receptor agonist suitable for chronic research protocols — properties that native amylin and earlier analogues could not provide.
Mechanism of Action
Amylin Receptor Agonism
Cagrilintide acts as a potent agonist at amylin receptors — heterodimeric complexes consisting of calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These receptor complexes are expressed in the area postrema, nucleus accumbens, hypothalamus, and peripheral tissues.
Amylin receptor activation in the area postrema drives vagal nerve signaling that reduces gastric emptying rate — directly controlling the speed of nutrient delivery to the small intestine and modulating postprandial glucose excursions. Hypothalamic amylin receptor activation reduces food intake through complementary but distinct circuits from GLP-1 receptor-mediated satiety signaling.
Glucagon Suppression
Amylin receptor activation suppresses glucagon secretion from pancreatic alpha cells — a complementary anti-hyperglycemic effect to insulin’s glucose-lowering action and GLP-1’s glucagon-suppressant activity. Research has investigated whether cagrilintide’s glucagon suppression is additive with GLP-1 receptor-mediated glucagon suppression in combination protocols.
Central Nervous System Effects
Amylin receptors in the nucleus accumbens and other limbic regions influence food reward circuitry — affecting not just satiety (how full you feel) but also the hedonic aspects of eating (how rewarding food is). This CNS mechanism is distinct from GLP-1 receptor-mediated appetite suppression and represents an additional pathway through which cagrilintide may reduce caloric intake in research models.
Research Applications
Metabolic and Obesity Research
The primary research application for cagrilintide concerns metabolic disease and obesity models. Research has examined its effects on body weight, food intake, gastric emptying rate, postprandial glucose excursions, and metabolic rate in relevant animal models. Its long half-life and stable once-weekly profile make it practical for chronic metabolic research protocols.
Combination Research with GLP-1 Receptor Agonists
The most scientifically significant application of cagrilintide in current research is its combination with GLP-1 receptor agonists. GLP-1 and amylin pathways are complementary — they both reduce food intake and body weight, but through distinct receptor systems and partially distinct mechanisms. Research has investigated whether co-administration produces additive or synergistic effects on metabolic outcomes compared to either pathway alone.
The combination of Semaglutide (GLP-1 agonist) + cagrilintide represents one of the most actively investigated dual-hormone metabolic research protocols currently studied. Research designs using this combination can dissect the relative contributions of GLP-1 receptor versus amylin receptor pathways to observed metabolic effects — valuable mechanistic data for understanding the full pharmacology of each pathway.
Similarly, cagrilintide combined with Tirzepatide (GLP-1/GIP dual agonist) creates a triple-hormone research protocol targeting GLP-1R, GIPR, and amylin receptors simultaneously — addressing three distinct but complementary metabolic regulatory systems in a single research design.
For researchers interested in the broader GLP-1 research landscape, see our overviews of Semaglutide, Tirzepatide vs Semaglutide, and Retatrutide — the first triple GLP-1/GIP/glucagon agonist.
Glucose Homeostasis Research
Cagrilintide’s effects on gastric emptying, glucagon suppression, and postprandial glucose excursions make it relevant to glucose homeostasis research beyond simple appetite and weight studies. Research has examined its effects on glucose tolerance, insulin requirements, and the relationship between gastric emptying rate and glycemic variability in relevant metabolic models.
Appetite Regulation and CNS Research
The amylin receptor’s distribution in appetite-regulating and reward-related brain regions makes cagrilintide a tool for CNS research on food intake regulation. Studies have examined its effects on meal patterns, food reward behavior, and CNS amylin receptor signaling in animal models — contributing to understanding of the neurobiology of appetite regulation beyond GLP-1 pathway mechanisms.
Cagrilintide in the AminoForge Metabolic Research Catalog
AminoForge carries the full range of metabolic research peptides for comprehensive GLP-1 axis and amylin research. Alongside cagrilintide, our metabolic research catalog includes Semaglutide (GLP-1 monoagonist), Tirzepatide (GLP-1/GIP dual agonist), Retatrutide (GLP-1/GIP/glucagon triagonist), AOD-9604 (hGH lipolytic fragment), MOTS-C (mitochondrial metabolic regulator), and 5-Amino-1MQ (NNMT inhibitor).
Shop Cagrilintide at AminoForge — ≥99% purity, third-party COA verified, USA manufactured, ships within 48 hours.
Formulation and Storage
Cagrilintide is available as a lyophilized powder. Reconstitute with bacteriostatic water. Store lyophilized at -20°C; reconstituted solutions at 2–8°C protected from light. Research-grade purity should be verified at ≥99% by HPLC with mass spectrometry confirmation of the approximately 3,985 Da molecular weight.
Amylin receptor agonism and metabolic regulation research
All products sold by AminoForge are intended exclusively for laboratory and research purposes. Not for human or veterinary consumption. Researchers are responsible for compliance with all applicable laws and regulations governing research compound use in their jurisdiction.